Duncan Taylor Ph.D.
Consultant to Business Development

Duncan P. Taylor, Ph.D., recently retired as Senior Director, Business Development, for SK Life Science Inc. He joined that company in 2008 and was responsible for the identification and evaluation of the strategic and financial prospects of new market opportunities and their pursuit. His 30+-year career in the pharmaceutical industry encompassed roles as Senior Director of Strategic Intelligence in Business Development with Biovail Pharmaceuticals for 3 years (now part of Valeant Pharmaceuticals), Director of Strategic Research Assessment for the Pharmacia Corporation (previously Pharmacia & Upjohn and now part of Pfizer) for 7 years, Director of Pharmacology for Symphony Pharmaceuticals, a privately-held start-up pharmaceutical research company, Senior Research Fellow for Bristol-Myers Squibb in Central Nervous System Biological Discovery for 15 years, and as an independent consultant.
His efforts during those tenures have succeeded in the successful in-licensing of Axert® (almotriptan), a treatment for migraine headaches, for North America; the discovery, approval, and marketing of Serzone® (nefazodone), a treatment for major depressive disorder; and significant contributions to the development, approval, and marketing of BuSpar® (buspirone), for generalized anxiety disorder, Stadol® NS (transnasal butorphanol), for the relief of moderate to severe pain, and Desyrel® (trazodone), for the treatment of depression. He has authored or co-authored over 50 monographs and published articles, 20 book chapters, and over 90 abstracts in the scientific literature; he and his associates have issued over 250 scientific, technical, and competitive intelligence internal reports; and he is the inventor or co-inventor on 21 issued patents and 28 published pending patent applications.
Dr. Taylor received his B.S. in chemistry from the California Institute of Technology, his Ph.D. in biochemistry from Oregon State University, and received a National Research Service Award from the National Institute on Drug Abuse for his work at the National Institute for Mental Health in Bethesda, MD. He has been elected to Sigma Xi and Phi Lambda Upsilon (research and chemistry honorary societies), is a Fellow of the American Institute of Chemists, and has been listed in numerous biographical listings since 1982. He is a past member of the Licensing Executives Society as well as a number other scientific and medical professional societies. Dr. Taylor lives in Flemington, NJ, with his wife of 42 years.